Vnitr Lek 2010, 56(6):613-619

Prevention and treatment of extremitovascular ischemic disease

P. Gavorník*, A. Dukát, Ľ. Gašpar, S. Oravec, M. Čaprnda, I. Vacula, D. Čelovská, A. Uhrinová, M. Kováčová, T. Pišková, K. Letková, A. Teren
Prvé angiologické pracovisko (PAP), vedúci lekár doc. MUDr. Peter Gavorník, PhD., mim. prof. II. internej kliniky Lekárskej fakulty UK - FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Andrej Dukát, CSc., FESC

Extremitovascular ischemic disease (peripheral arterial disease of extremities - PAD) is an important manifestation of systemic atherosclerosis and other arterial diseases of vascular system. The lower the anklebrachial pressure index, the greater the risk of serious cardiovascular events (e. g. acute myocardial infarction, stroke). Prevention and treatment of extremitovascular disease is discussed in this article.

Keywords: extremitovascular ischemic disease; peripheral arterial disease; prevention; treatment; nondrug therapy; drug therapy

Received: May 30, 2010; Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gavorník P, Dukát A, Gašpar Ľ, Oravec S, Čaprnda M, Vacula I, et al.. Prevention and treatment of extremitovascular ischemic disease. Vnitr Lek. 2010;56(6):613-619.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gavorník P. Etiopatogenéza a nová klinicko-etiologicko-anatomicko-patofyziologická (CEAP) klasifikácia končatinovocievnej ischemickej choroby. Interná Med 2010; 10: 115-123.
    2. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. (Constituted by reepresentatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-2414.
    3. Gavorník P. Angiológia. Bratislava: Univerzita Komenského - Vydavateľstvo UK 1998.
    4. Gavorník P. Ateroskleróza a iné choroby tepien. Bratislava: Univerzita Komenského - Vydavateľstvo UK 1999.
    5. Gavorník P. Cievne choroby. 382-400. In: Klimo F et al (eds). Praktické a rodinné lekárstvo. Senica: Prognóza 1999.
    6. Gavorník P. Choroby tepien. In: Ďuriš I, Hulín I, Bernadič M (eds). Princípy internej medicíny. Bratislava: Slovac Academic Press 2001: 784-797.
    7. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. Bratislava: Univerzita Komenského - Vydavateľstvo UK 2001.
    8. TASC - Management of peripheral arterial disease. TransAtlantic Inter - Society Consensus (TASC). Int Angiol 2000; 19: (Suppl. 1): 1-310. Go to PubMed...
    9. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus and Vascular Disease Foundation. Circulation 2006; 113: e463-e654. Go to original source... Go to PubMed...
    10. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-S75. Go to original source... Go to PubMed...
    11. Štvrtinová V, Šefránek V, Murín J et al. Odporúčania pre diagnostiku a liečbu periférneho artériového ochorenia končatín. Odporúčania Slovenskej angiologickej spoločnosti, Slovenskej spoločnosti pre cievnu chirurgiu, Slovenskej kardiologickej spoločnosti, Slovenskej internistickej spoločnosti a Slovenskej rádiologickej spoločnosti. Cardiol 2006; 15: 317-323.
    12. Bada V. Výživa ako prevencia kardiovaskulárnych chorôb. Kardiológia pre Prax 2009; 7: 91-96.
    13. Gavorník P, Kolesár P, Hudec I et al. Význam kinezioterapie ischemickej choroby dolných končatín u chorých s rodinnými hyperlipoproteinémiami. Vnitř Lék 1981; 27: 72-79. Go to PubMed...
    14. Gavorník P, Kolesár J, Dukát A. Pohybová liečba (kinezioterapia) ischemickej choroby dolných končatín III. štádia. Vnitř Lék 1986; 32: 597-604. Go to PubMed...
    15. Gavorník P, Holomáň M, Kolesár J et al. Kinezioterapia ischemickej choroby dolných končatín u chorých po rekonštrukčnej operácii tepien. Čas Lék Čes 1986; 125: 1000-1003.
    16. Šefránek V. Ochorenia končatinových tepien a ich chirurgická liečba. Bratislava: SAP 2001.
    17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III. Final Report. Circulation 2002; 106: 3143-3421. Go to original source...
    18. Fruchart JC, Sacks FM, Hermans MP et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. Am J Cardiol 2008; 102 (Suppl 10): 1K-34K. Go to original source... Go to PubMed...
    19. Residual Risk Reduction Initiative. Available from: www.r3i.org.
    20. ACCORD Lipid Study brings new hope to people with type 2 diabetes and atherogenic dyslipidemia says international academic foundation. Available from: http://multivu.prnewswire.com/mnr/r3i/42622/.
    21. Dukát A. Reziduálne kardiovaskulárne riziko závažný problém, ktorý si bude vyžadovať nové liečebné prístupy. Cardiol 2008; 17: 229-233.
    22. The seventh American College of Chest Physicians (ACCP) conference on antithrombotic and thrombolytic therapy. From evidence to application. Chest 2004; 126 (Suppl 3): 172S-696S. Go to PubMed...
    23. Antithrombotic and thrombolytic therapy: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (Suppl 6): 67S-968S.
    24. Gavorník P. Artériotromboprofylaxia v klinickej praxi. Cardiol 2010; 19: 155-158.
    25. Remková A. Aktuálne otázky antidoštičkovej liečby kyselinou acetylsalicylovou v primárnej a sekundárnej prevencii cievnych ochorení u diabetikov. Interná Med 2007; 7: 36-39. Go to original source...
    26. Pecka M, Malý J. Metabolické a aktivačné děje v krevních deštičkách a možnosti jejich inhibice. Vnitř Lék 2009; 55: 263-266. Go to PubMed...
    27. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1620. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.